H-Index & Metrics Best Publications

H-Index & Metrics

Discipline name H-index Citations Publications World Ranking National Ranking
Medicine D-index 124 Citations 100,134 432 World Ranking 1325 National Ranking 801

Research.com Recognitions

Awards & Achievements

Member of the Association of American Physicians

Overview

What is he best known for?

The fields of study he is best known for:

  • Cancer
  • Internal medicine
  • Breast cancer

Daniel F. Hayes mostly deals with Breast cancer, Internal medicine, Oncology, Cancer and Surgery. His study in Breast cancer is interdisciplinary in nature, drawing from both Clinical Oncology, Guideline, Gynecology and Radiation therapy. His study in Internal medicine is interdisciplinary in nature, drawing from both Endocrinology and Pathology.

The various areas that Daniel F. Hayes examines in his Oncology study include Prospective cohort study, Metastatic breast cancer, Metastasis and Chemotherapy. His work focuses on many connections between Cancer and other disciplines, such as Cancer research, that overlap with his field of interest in Stem cell, Cancer stem cell, Prostate cancer, Drug resistance and In vitro. His study looks at the relationship between Surgery and topics such as General surgery, which overlap with Lymph node, Managed care, Retrospective cohort study and Medical record.

His most cited work include:

  • American society of clinical oncology/college of american pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer (3788 citations)
  • Circulating Tumor Cells, Disease Progression, and Survival in Metastatic Breast Cancer (3458 citations)
  • ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome (3056 citations)

What are the main themes of his work throughout his whole career to date?

The scientist’s investigation covers issues in Internal medicine, Breast cancer, Oncology, Cancer and Chemotherapy. His research links Endocrinology with Internal medicine. In Breast cancer, Daniel F. Hayes works on issues like Gynecology, which are connected to Guideline.

His Oncology research also works with subjects such as

  • Cyclophosphamide which intersects with area such as Doxorubicin,
  • Pathology, which have a strong connection to Biomarker. He combines subjects such as Adjuvant and Anthracycline with his study of Chemotherapy. The Metastatic breast cancer study combines topics in areas such as Metastasis and CA15-3.

He most often published in these fields:

  • Internal medicine (68.58%)
  • Breast cancer (64.68%)
  • Oncology (56.06%)

What were the highlights of his more recent work (between 2016-2021)?

  • Internal medicine (68.58%)
  • Breast cancer (64.68%)
  • Oncology (56.06%)

In recent papers he was focusing on the following fields of study:

Daniel F. Hayes mainly focuses on Internal medicine, Breast cancer, Oncology, Cancer and Chemotherapy. Many of his studies involve connections with topics such as Cancer research and Breast cancer. When carried out as part of a general Oncology research project, his work on Adjuvant is frequently linked to work in In patient, therefore connecting diverse disciplines of study.

Daniel F. Hayes interconnects Log-rank test and Osteonecrosis of the jaw in the investigation of issues within Cancer. His Chemotherapy study combines topics from a wide range of disciplines, such as Tamoxifen, Single-nucleotide polymorphism, Tumor-infiltrating lymphocytes and Anthracycline. His studies deal with areas such as Survival analysis and Metastasis, Circulating tumor cell as well as Metastatic breast cancer.

Between 2016 and 2021, his most popular works were:

  • Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer (685 citations)
  • Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer (685 citations)
  • De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017. (494 citations)

In his most recent research, the most cited papers focused on:

  • Cancer
  • Internal medicine
  • Breast cancer

His main research concerns Internal medicine, Breast cancer, Oncology, Cancer and Chemotherapy. Internal medicine is closely attributed to Guideline in his study. As a member of one scientific family, Daniel F. Hayes mostly works in the field of Guideline, focusing on Asco cap and, on occasion, Progesterone receptor.

His work carried out in the field of Breast cancer brings together such families of science as Prospective cohort study, Chemotherapy regimen and Radiation therapy. His Oncology study integrates concerns from other disciplines, such as Clinical Oncology, Metastatic breast cancer, Randomized controlled trial, Hazard ratio and Triple-negative breast cancer. His Cancer research incorporates themes from Molecular biology, Cancer research and Survival analysis.

This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.

Best Publications

American society of clinical oncology/college of american pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer

Antonio C. Wolff;M. Elizabeth H. Hammond;Jared N. Schwartz;Karen L. Hagerty.
Journal of Clinical Oncology (2006)

7112 Citations

American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer

M. Elizabeth H. Hammond;Daniel F Hayes;Mitch Dowsett;D Craig Allred.
Journal of Clinical Oncology (2010)

5170 Citations

American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer.

Antonio C. Wolff;M. Elizabeth H. Hammond;Jared N. Schwartz;Karen L. Hagerty.
Archives of Pathology & Laboratory Medicine (2007)

4833 Citations

Circulating Tumor Cells, Disease Progression, and Survival in Metastatic Breast Cancer

Massimo Cristofanilli;G. Thomas Budd;Matthew J. Ellis;Alison Stopeck.
The New England Journal of Medicine (2004)

4519 Citations

ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome

Christophe Ginestier;Min Hee Hur;Emmanuelle Charafe-Jauffret;Florence Monville.
Cell Stem Cell (2007)

4191 Citations

Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013

A Goldhirsch;E P Winer;A S Coates;R D Gelber.
Annals of Oncology (2013)

2956 Citations

American Society of Clinical Oncology 2007 Update of Recommendations for the Use of Tumor Markers in Breast Cancer

Lyndsay Harris;Herbert Fritsche;Robert Mennel;Larry Norton.
Journal of Clinical Oncology (2007)

2762 Citations

Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update

Antonio C. Wolff;M. Elizabeth H Hammond;David G. Hicks;Mitch Dowsett.
Journal of Clinical Oncology (2013)

1998 Citations

EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells

Celina G. Kleer;Qi Cao;Sooryanarayana Varambally;Ronglai Shen.
Proceedings of the National Academy of Sciences of the United States of America (2003)

1753 Citations

Improved Outcomes From Adding Sequential Paclitaxel but Not From Escalating Doxorubicin Dose in an Adjuvant Chemotherapy Regimen for Patients With Node-Positive Primary Breast Cancer

I. Craig Henderson;Donald A. Berry;George D. Demetri;Constance T. Cirrincione.
Journal of Clinical Oncology (2003)

1728 Citations

If you think any of the details on this page are incorrect, let us know.

Contact us

Best Scientists Citing Daniel F. Hayes

Gabriel N. Hortobagyi

Gabriel N. Hortobagyi

The University of Texas MD Anderson Cancer Center

Publications: 196

Giuseppe Viale

Giuseppe Viale

European Institute of Oncology

Publications: 190

Massimo Cristofanilli

Massimo Cristofanilli

Northwestern University

Publications: 181

Klaus Pantel

Klaus Pantel

Universität Hamburg

Publications: 166

Ian O. Ellis

Ian O. Ellis

University of Nottingham

Publications: 153

Mitch Dowsett

Mitch Dowsett

Breast Cancer Research Foundation

Publications: 140

Eric P. Winer

Eric P. Winer

Harvard University

Publications: 137

Emad A. Rakha

Emad A. Rakha

University of Nottingham

Publications: 137

Jorge S. Reis-Filho

Jorge S. Reis-Filho

Memorial Sloan Kettering Cancer Center

Publications: 133

Nadia Harbeck

Nadia Harbeck

Ludwig-Maximilians-Universität München

Publications: 125

Max S. Wicha

Max S. Wicha

University of Michigan–Ann Arbor

Publications: 123

Lajos Pusztai

Lajos Pusztai

Yale University

Publications: 123

Andreas Schneeweiss

Andreas Schneeweiss

German Cancer Research Center

Publications: 113

Jonas Bergh

Jonas Bergh

Karolinska University Hospital

Publications: 109

Martine Piccart

Martine Piccart

Université Libre de Bruxelles

Publications: 105

Clifford A. Hudis

Clifford A. Hudis

Memorial Sloan Kettering Cancer Center

Publications: 104

Something went wrong. Please try again later.